Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04512066 · ClinicalTrials.gov registry record · Phase 2
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 287
- Enrollment target
NCT04512066 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 287 participants.
The verdict
NCT04512066, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 287 participants
- Enrollment target
Study Summary
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG RO6889450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04512066
The ClinicalTrials.gov registry entry for NCT04512066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04512066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04512066 about?
NCT04512066 is a clinical study titled "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder". This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
What is the current status of trial NCT04512066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 287 participants. The study started on 2020-09-08. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT04512066?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), RO6889450 (DRUG).
Who is sponsoring clinical trial NCT04512066?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.